CellaVision receives first order from the Veterinary market
(Thomson Reuters ONE) -
CellaVision has received its first order for the analyzer, CellaVision ® DM96
Vet System which was launched in the North American Veterinary market in the
early part of 2012. The order was placed by one of North America's largest
veterinary reference laboratory chains with operations at many locations.
"We are delighted to see the first order from the veterinary market. With this
order we have equipped the first of many reference laboratories with the
CellaVision ® DM96 Vet System. This is an important first step which will help
make the Veterinary lab market aware of the value of CellaVision's solutions.
The order is of strategic value for us because the product provides us with
additional growth opportunities in our core market segment, hematology, "says
Yvonne Mårtensson, CEO of CellaVision.
The CellaVision DM96 Vet System replaces the manual microscope for performing
blood differentials in veterinary laboratories, the same way it does in the
human market. The product is a customized version of CellaVision's existing
instruments for human blood with the capacity to analyze the blood of companion
animals, e.g., cats and dogs. The initial target group is the over one hundred
large veterinary laboratories in the U.S. and Canada, where the volume of
samples is high and the need for efficient analysis method is great. A key
driver in this market is the utilization of CellaVision® Remote Review Software
which will allow a lab's differentials to be performed from any external
location. In Europe and other geographic markets, companion animal blood
analyses are often not performed in the reference laboratories but rather are
done in smaller veterinary laboratories or human hospital laboratories.
CellaVision sells the product directly to the end customer.
For further information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. Email: yvonne.martensson(at)cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops
and sells its own leading systems for routine analysis of blood and other body
fluids in health care services. The analyses often constitute important
reference data for fast and correct diagnosis of illnesses, for example of
infections and serious cancers. CellaVision's products rationalize manual
laboratory work, and secure and support effective workflows and skills
development within and between hospitals. The company has leading-edge expertise
in image analysis, artificial intelligence and automated microscopy. In 2011
sales were SEK 155 million and sales continue to increase, with a growth target
of at least 15 % per year over an economic cycle. CellaVision's registered
office is in Lund and the company has subsidiaries in the USA, Canada and Japan.
The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at
www.cellavision.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1636461]
Unternehmensinformation / Kurzprofil:
Datum: 28.08.2012 - 08:31 Uhr
Sprache: Deutsch
News-ID 178015
Anzahl Zeichen: 3733
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 124 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision receives first order from the Veterinary market"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
